Potential Approach for Treating T-Cell Acute Lymphoblastic Leukemia Uncovered
Researchers find that blocking one or more genes in the HSF1 pathway could represent a new approach in treating the rare, aggressive disease.
Can Polio Be Used to Treat Glioblastoma?
Investigators explore if polio can be used as a potential treatment for glioblastoma, an aggressive form of cancer that currently has no cure.
Yale Scientists Identify Potential Treatment for Rare Hereditary Cancer Syndromes
Yale Cancer Center scientists find that some rare hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair.
AML Family Trees Shed Light on Responsiveness to Enasidenib
Researchers map family trees of cancer cells in acute myeloid leukemia to better understand how the cancer responds to new drug, enasidenib.
Altitude Sickness Drug May Help Glioblastoma Patients
Researchers say that adding a common altitude sickness drug to the treatment protocol for patients with glioblastoma may improve the effectiveness of chemotherapy and extend survival in some patients.
Molecular Events, Not Time, Define Pediatric Oncology Outcomes
E. Anders Kolb, MD, outlines the challenges in diagnosing pediatric cancers and explains how molecular events define disease outcomes.
Top 5 Rare Disease News of the Week—July 15, 2018
Stay up-to-date on the latest rare disease news by reading the top 5 articles of the week.
FDA Approves First Targeted Treatment for Certain Patients with Acute Myeloid Leukemia
The FDA has approved ivosidenib tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia who have a specific genetic mutation.
Multiple Myeloma Treatment, Galinpepimut-S, Receives FDA Fast Track Designation
The US Food and Drug Administration (FDA) has granted fast track designation to galinpepimut-S (GPS) for the treatment of multiple myeloma.
Metastatic Hepatocellular Carcinoma Treatment Receives Breakthrough Therapy Designation
The FDA has granted a breakthrough therapy for atezolizumab Tin combination with bevacizumab for the treatment of advanced or metastatic hepatocellular carcinoma.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2019 Rare Disease Communications. All Rights Reserved.